Resolution on the results of the expert panel «IDegLira: is it 1 + 1 or anything more?»


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

On June 19, 2020, an expert panel meeting under the chairmanship of Dr.Sci.(Med.), Professor M.B. Antsiferov was held in Moscow; it was dedicated to the discussion of the latest results of clinical trials of the use of the combined preparation insulin degludec+liraglutide, IDegLira (Sultofay® FlexTouch®) for the treatment of patients with diabetes mellitus (DM) of various groups. The aim of the meeting was to determine the role and place of the drug insulin degludec+liraglutide, IDegLira (Sultofay® FlexTouch®) in the DM2 treatment in real clinical practice based on its benefits confirmed in clinical trials. Thus, the combined drug IDegLira is an effective antihyperglycemic drug that affects different links in the DM2 pathogenesis and makes it possible to personalize DM2 therapy, taking into account the existing complications and concomitant diseases.

Full Text

Restricted Access

About the authors

Mikhail B. Antsiferov

Endocrinological Dispensary of the Moscow Healthcare Department

Email: antsiferov@rambler.ru
Dr. Sci. (Med.), Professor, Chief Freelance Expert in Endocrinology of the Moscow Healthcare Department, Chief Physician of the Endocrinological Dispensary; Honored Doctor of Moscow and the Russian Federation 37, Prechistenka str., Moscow 119034, Russian Federation

G. R Galstyan

National Medical Research Center of Endocrinology

Moscow, Russia

References

  1. International Diabetes Federation. IDF Diabetes Atlas, 9th ed. Brussels, Belgium: 2019. Available at: https://www.diabetesatlas.org. Accessed 20Jul 2020.
  2. Дедов И.И., Шестакова М.В., Викулова О.К. Эпидемиология сахарного диабета в Российской Федерации: клинико-статистический анализ по данным Федерального регистра сахарного диабета. Сахарный диабет. 2017;20(1):13-41. doi: 10.14341/DM8664.
  3. Шестакова М.В., Викулова О.К., Железнякова А.В. и др. Эпидемиология сахарного диабета в Российской Федерации: что изменилось за последнее десятилетие? Терапевтический архив. 2019;91(10):4-13. doi: 10.26442/00403660. 2019.10.000364.
  4. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 9-й выпуск (дополненный). М., 2019. doi: 10.14341/DM221S1.
  5. Шестакова М.В. Программа по преодолению барьеров в лечении сахарного диабета. По материалам Международного исследования DAWN. Сахарный диабет. 2004;1:50-3.
  6. Jonassen I., Havelund S., Hoeg-Jensen T., et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res. 2012;29(8):2104-14. Doi: 10.1007/ s11095-012-0739-z.
  7. Heise T., Hermanski L., Nosek L., et al. IDeg: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabet Obes Metab. 2012;14:859-64.
  8. Heise T., Norskov M., Nosek L., et al. Insulin degludec: lower day-to-day and withinday variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes. Diabet Obes Metab. 2017;19:1032-39.
  9. Ratner R.E., Gough S.C., Mathieu C., et al. Hypoglycaemia risk with IDeg compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabet Obes Metab. 2013;15:175-84.
  10. Rigato М., Fadini G.P Comparative effectiveness of liraglutide in the treatment of type 2 diabetes. Diabet Metab Syndr Obes. 2014;7:107-20. doi: 10.2147/DMSO.S37644.
  11. Flint A., Kapitza C., Hindsberger C., Zdravkovic M. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients. Adv Ther. 2011;28:213-26. doi: 10.1007/s12325-010-0110-x.
  12. Degn K.B., Juhl C.B., Sturis J., et al. One week's treatment with the long-acting glucagonlike peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha-and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabet. 2004;53:1187-94. doi: 10.2337/diabetes.53.5.1187.
  13. Baggio L.L., Drucker D.J. Biology of incretins: GLP-1 and GIP Gastroenterol. 2007;132:2131-57. doi: 10.1053/j.gastro.2007.03.054.
  14. Vilsb0ll T., Christensen M., Junker A.E., et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771. doi: 10.1136/bmj. d7771.
  15. Horowitz M., Flint A., Jones K.L., et al. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. Diabet Res Clin Pract. 2012;97:258-66. doi: 10.1016/j.diabres.2012.02.016.
  16. Niswender K., Pi-Sunyer X., Buse J., et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabet Obes Metab. 2013;15:42-54. doi: 10.1111/j.1463-1326.2012.01673.x.
  17. Fonseca V., et al. Liraglutide, a once-daily human GLP-1 analog, lowers systolic blood pressure (SBP) independently of concomitant antihypertensive treatment. Diabetes. 2010;59(Suppl. 1):A79(296-OR).
  18. Jonassen I., Havelund S., Hoeg-Jensen T., et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res. 2012;29:2104-14. doi: 10.1007/s11095-012-0739-z.
  19. Steensgaard et al. The effects of glucagonlike peptide-1 on the beta cell. Diabetes. 2008;57(Suppl. 1):A164 (Abstract 552-P). doi: 10.1111/j.1463-1326.2009.01073.x.
  20. Kapitza C., Bode B., Ingwersen S.H., et al. Preserved pharmacokinetic exposure and distinct glycemic effects of insulin degludec and liraglutide in IDegLira, a fixed-ratio combination therapy. J Clin Pharmacol. 2015;55:1369-77. doi: 10.1002/jcph.549.
  21. Gough S.C., Bode B.W., Woo VC., et al. One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial. Diabet Obes Metab. 2015;17:965- 73. doi: 10.1111/dom.12498.
  22. Brod M., et al. Patient-Reported Outcomes (PROs) for Insulin Degludec/Liraglutide (IDegLira) vs. Insulin Glargine (IGlar U100) as Add-On to Sodium-Glucose Co-Transporter-2 Inhibitor (SGLT2i)±Oral Antidiabetic Drug (OAD) Therapy in Patients with Type 2 Diabetes (T2D) - DUAL IX Trial. Diabetes 2018;67(Suppl. 1). doi: 10.2337/db18-101-LB.
  23. Philis-Tsimikas A., Billings L.K., Busch R. et al. Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes. Diabet Obes Metab. 2019;21(6):1399-408. doi: 10.1111/dom.13666.
  24. Linjawi S., Bode B.W., Chaykin L.B., et al. The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial. Diabet Ther. 2017;8:101-14. doi: 10.1007/s13300-016-0218-3.
  25. Billings L.K., et al. Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial. Diabet Care. 2018;41(5):1009-16. doi: 10.2337/dc17-1114.
  26. Price H., et al. Use and effectiveness of a fixed ratio combination of insulin degludec/liraglutide (IDegLira) in a real-world population with type 2 diabetes: Results from a European, multicentre, retrospective chart review study. Diab. Obes. Metab. 2017;5: doi: 10.1111/dom.13182.
  27. Sofra D. Glycemic Control in a Real-Life Setting in Patients with Type 2 Diabetes Treated with IDegLira at a Single Swiss Center Diabet Ther. 2017;8:377-84. doi: 10.1007/s13300-017-0234-y.
  28. Drummond R., Baru A., Dutkiewicz M., et al. Physicians' real-world experience with IDegLira: results of a European survey. BMJ. Open Diabet Res Care. 2018;6(1):e000531. doi: 10.1136/bmjdrc-2018-000531.
  29. Aroda V.R., et al. Oral Semaglutide - The PIONEER Program Trials. ADA highlights 2019.
  30. Lingvay I., Pérez Manghi F., Garcia-Hernandez P. et al. Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial. JAMA. 2016;315:898-907. doi: 10.1001/jama.2016.1252.
  31. Sorli С, et al. Diabetes 2016;65(Suppl. 1):A238 (Abstract 925-P).
  32. Billings L.K., et al. Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial. Diabet Care. 2018;41(5):1009-16. doi: 10.2337/dc17-1114.
  33. Evans M, Billings L.K., Hâkan-Blochet J., et al. An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin. J Med Econ. 2018; 21(4):340-47. doi: 10.1080/13696998.2017.1409228.
  34. Marso S.P., et al. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. N Engl J Med. 2017;377(8):723-32. Doi: 10.1056/ NEJMoa1615692.
  35. Marso S.P., et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-22. doi: 10.1056/NEJMoa1603827.
  36. Davies M.J., DAlessio D.A., Fradkin J., et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabet Care. 2018;41(12):2669-701. doi: 10.2337/dci18-0033.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies